Beoordeling of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patiënten met Non-Small Cell Longkanker After Chemoradiotherapie: A Multicenter Studie
The effective dose to immune cells–radiotherapy course–adjusted (EDRIC) is a dosimetry-based metric that estimates radiation exposure to circulating immune cells during radiotherapy.
Abstract (original)
The effective dose to immune cells–radiotherapy course–adjusted (EDRIC) is a dosimetry-based metric that estimates radiation exposure to circulating immune cells during radiotherapy. Elevated EDRIC is linked to lymphopenia, immune dysfunction, and poor tumor control in unresectable non-small cell lung cancer (NSCLC) after chemoradiation. However, it is unclear if EDRIC directly correlates with clinical outcomes and particularly with durvalumab consolidation, or if confounding factors drive this association.
Dit artikel is een samenvatting van een publicatie in Int J Radiation Oncology. Voor het volledige artikel, alle details en referenties verwijzen wij u naar de oorspronkelijke bron.
Lees het volledige artikelDOI: 10.1016/j.ijrobp.2025.11.004